Japan approves Pfizer's COVID-19 vaccine

14 February 2021 - Japan formally approved Pfizer Inc's coronavirus vaccine on Sunday, the first greenlit for domestic use, clearing ...

Read more →

Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

25 January 2021 - 88% of patients on Calquence remained free of disease progression after 12 months vs. 68% for ...

Read more →

BioCryst announces approval of Orladeyo (berotralstat) in Japan for the prophylactic treatment of hereditary angioedema

22 January 2021 - BioCryst Pharmaceuticals today announced that the Ministry of Health, Labor and Welfare in Japan has granted ...

Read more →

Yescarta approved in Japan for treatment of patients with relapsed/refractory large B-cell lymphomas

22 January 2021 - Approval based on phase 2 study conducted in Japan and previous pivotal trial data. ...

Read more →

Myriad Genetics receives first reimbursement decision for myChoice diagnostic system in Japan, enabling women with ovarian cancer to benefit from treatment with Zejula

8 January 2021 - Myriad Genetics announced today that it received its first reimbursement decision for the Myriad myChoice Diagnostic System, ...

Read more →

Daiichi Sankyo submits application for oncolytic virus teserpaturev (G47∆) for treatment of patients with malignant glioma in Japan

5 January 2020 - Daiichi Sankyo and the University of Tokyo are collaboratively developing teserpaturev, which has received SAKIGAKE designation and ...

Read more →

Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

28 December 2020 - Approvals based on the PAOLA-1, PROfound and POLO Phase III trials ...

Read more →

Japan to lower drug prices to reduce medical costs

17 December 2020 - Japanese Finance Minister Taro Aso and health minister Norihisa Tamura agreed Thursday to reduce state-set prices ...

Read more →

Astellas receives approval of Evrenzo (roxadustat) in Japan for the treatment of anaemia of chronic kidney disease in adult patients not on dialysis

27 November 2020 - Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with ...

Read more →

Forxiga approved in Japan for chronic heart failure

30 November 2020 - Forxiga is the first SGLT2 inhibitor approved in Japan for chronic heart failure with reduced ejection ...

Read more →

Brickell Biotech announces launch date for sofpironium bromide 5% gel (Ecclock) in Japan by its development partner, Kaken Pharmaceutical

18 November 2020 - Kaken plans to launch Ecclock for the treatment of primary axillary hyperhidrosis in Japan on 26 November ...

Read more →

Kyowa Kirin announces approval for partial change of rituximab biosimilar received by Sandoz in Japan

18 November 2020 - Kyowa Kirin today announced that Sandoz KK, its strategic partner of the anti-CD20 monoclonal antibody rituximab ...

Read more →

Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan

19 October 2020 - Fujifilm said it was seeking approval for its flu drug Avigan as a treatment for COVID-19 in ...

Read more →

Ultomiris (ravulizumab) receives approval in Japan for atypical haemolytic uraemic syndrome in adults and children

25 September 2020 - Ultomiris is the first and only long-acting C5 inhibitor for atypical haemolytic uraemic syndrome, reducing the treatment ...

Read more →

Enhertu approved in Japan for the treatment of patients with HER2 positive metastatic gastric cancer

25 September 2020 - Approval of SAKIGAKE designated medicine is based on pivotal phase 2 DESTINY-Gastric01 trial and represents second approval ...

Read more →